Practical Reviews

No Renal Toxicity With Repeated 177Lu-PSMA-617 for Tx of HRMPC

Background: 177 Lu-PSMA-617 offers a promising targeted radionuclide therapy option for treatment of hormone-refractory metastatic prostate cancer (HRMPC). Though treatment is well tolerated, renal toxicity in patients receiving repeated cycles and effect on renal function is unknown. Objective: To evaluate post-treatment changes in renal function and incidence of acute and subacute renal failure after treatment with repeated cycles of 177 Lu-PSMA-617 and identify risk factors for more...
To view this content, you must be a logged in subscriber to
Please Login to view this content.